Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 adjunctive valbenazine in schizophrenia with inadequate antipsychotic response
2021-003714-39Phase 3Active
- Sponsor
- Neurocrine Biosciences
- Start
- Apr 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Valbenazine adjunctive arm with Placebo adjunctive arm (2 arms). Primary endpoint: Change in PANSS total score from baseline to Week 10. Started Apr 2022; status: active.
02
Drugs
valbenazine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2021-003714-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003714-39.